NASDAQ:IMGN - ImmunoGen Stock Price, Forecast & News

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMGN shares have increased by 5.3% and is now trading at $3.55. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen.

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for ImmunoGen.

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, February, 14th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.08. The biotechnology company earned $44.86 million during the quarter, compared to analysts' expectations of $29.24 million. View ImmunoGen's earnings history.

ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $44.62 million.

4 Wall Street analysts have issued 12-month price objectives for ImmunoGen's shares. Their forecasts range from $2.94 to $9.00. On average, they expect ImmunoGen's share price to reach $5.97 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price. View analysts' price targets for ImmunoGen.

News articles about IMGN stock have trended very negative on Monday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmunoGen earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutImmunoGen.

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Micron Technology (MU), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Exelixis (EXEL), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO) and Alibaba Group (BABA).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.15%), Palo Alto Investors LP (3.96%), State Street Corp (3.57%), Geode Capital Management LLC (1.62%), Panagora Asset Management Inc. (1.41%) and Pinnacle Associates Ltd. (0.85%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View institutional ownership trends for ImmunoGen.

IMGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC, Bank of America Corp DE, Pinnacle Associates Ltd., Stifel Financial Corp, and Raymond James & Associates. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Mark J Enyedy, and Thomas Ryll. View insider buying and selling activity for ImmunoGen.

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Public Sector Pension Investment Board, Jacobs Levy Equity Management Inc., and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for ImmunoGen.

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMGN stock can currently be purchased for approximately $3.55.

ImmunoGen has a market capitalization of $618.84 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe. View additional information about ImmunoGen.

The official website for ImmunoGen is http://www.immunogen.com/.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]